Detecting COVID-19 infection hotspots in England using large-scale self-reported data from a mobile application: a prospective, observational study.


Journal

The Lancet. Public health
ISSN: 2468-2667
Titre abrégé: Lancet Public Health
Pays: England
ID NLM: 101699003

Informations de publication

Date de publication:
01 2021
Historique:
received: 20 10 2020
revised: 10 11 2020
accepted: 12 11 2020
pubmed: 7 12 2020
medline: 15 1 2021
entrez: 6 12 2020
Statut: ppublish

Résumé

As many countries seek to slow the spread of COVID-19 without reimposing national restrictions, it has become important to track the disease at a local level to identify areas in need of targeted intervention. In this prospective, observational study, we did modelling using longitudinal, self-reported data from users of the COVID Symptom Study app in England between March 24, and Sept 29, 2020. Beginning on April 28, in England, the Department of Health and Social Care allocated RT-PCR tests for COVID-19 to app users who logged themselves as healthy at least once in 9 days and then reported any symptom. We calculated incidence of COVID-19 using the invited swab (RT-PCR) tests reported in the app, and we estimated prevalence using a symptom-based method (using logistic regression) and a method based on both symptoms and swab test results. We used incidence rates to estimate the effective reproduction number, R(t), modelling the system as a Poisson process and using Markov Chain Monte-Carlo. We used three datasets to validate our models: the Office for National Statistics (ONS) Community Infection Survey, the Real-time Assessment of Community Transmission (REACT-1) study, and UK Government testing data. We used geographically granular estimates to highlight regions with rapidly increasing case numbers, or hotspots. From March 24 to Sept 29, 2020, a total of 2 873 726 users living in England signed up to use the app, of whom 2 842 732 (98·9%) provided valid age information and daily assessments. These users provided a total of 120 192 306 daily reports of their symptoms, and recorded the results of 169 682 invited swab tests. On a national level, our estimates of incidence and prevalence showed a similar sensitivity to changes to those reported in the ONS and REACT-1 studies. On Sept 28, 2020, we estimated an incidence of 15 841 (95% CI 14 023-17 885) daily cases, a prevalence of 0·53% (0·45-0·60), and R(t) of 1·17 (1·15-1·19) in England. On a geographically granular level, on Sept 28, 2020, we detected 15 (75%) of the 20 regions with highest incidence according to government test data. Our method could help to detect rapid case increases in regions where government testing provision is lower. Self-reported data from mobile applications can provide an agile resource to inform policy makers during a quickly moving pandemic, serving as a complementary resource to more traditional instruments for disease surveillance. Zoe Global, UK Government Department of Health and Social Care, Wellcome Trust, UK Engineering and Physical Sciences Research Council, UK National Institute for Health Research, UK Medical Research Council and British Heart Foundation, Alzheimer's Society, Chronic Disease Research Foundation.

Sections du résumé

BACKGROUND
As many countries seek to slow the spread of COVID-19 without reimposing national restrictions, it has become important to track the disease at a local level to identify areas in need of targeted intervention.
METHODS
In this prospective, observational study, we did modelling using longitudinal, self-reported data from users of the COVID Symptom Study app in England between March 24, and Sept 29, 2020. Beginning on April 28, in England, the Department of Health and Social Care allocated RT-PCR tests for COVID-19 to app users who logged themselves as healthy at least once in 9 days and then reported any symptom. We calculated incidence of COVID-19 using the invited swab (RT-PCR) tests reported in the app, and we estimated prevalence using a symptom-based method (using logistic regression) and a method based on both symptoms and swab test results. We used incidence rates to estimate the effective reproduction number, R(t), modelling the system as a Poisson process and using Markov Chain Monte-Carlo. We used three datasets to validate our models: the Office for National Statistics (ONS) Community Infection Survey, the Real-time Assessment of Community Transmission (REACT-1) study, and UK Government testing data. We used geographically granular estimates to highlight regions with rapidly increasing case numbers, or hotspots.
FINDINGS
From March 24 to Sept 29, 2020, a total of 2 873 726 users living in England signed up to use the app, of whom 2 842 732 (98·9%) provided valid age information and daily assessments. These users provided a total of 120 192 306 daily reports of their symptoms, and recorded the results of 169 682 invited swab tests. On a national level, our estimates of incidence and prevalence showed a similar sensitivity to changes to those reported in the ONS and REACT-1 studies. On Sept 28, 2020, we estimated an incidence of 15 841 (95% CI 14 023-17 885) daily cases, a prevalence of 0·53% (0·45-0·60), and R(t) of 1·17 (1·15-1·19) in England. On a geographically granular level, on Sept 28, 2020, we detected 15 (75%) of the 20 regions with highest incidence according to government test data.
INTERPRETATION
Our method could help to detect rapid case increases in regions where government testing provision is lower. Self-reported data from mobile applications can provide an agile resource to inform policy makers during a quickly moving pandemic, serving as a complementary resource to more traditional instruments for disease surveillance.
FUNDING
Zoe Global, UK Government Department of Health and Social Care, Wellcome Trust, UK Engineering and Physical Sciences Research Council, UK National Institute for Health Research, UK Medical Research Council and British Heart Foundation, Alzheimer's Society, Chronic Disease Research Foundation.

Identifiants

pubmed: 33278917
pii: S2468-2667(20)30269-3
doi: 10.1016/S2468-2667(20)30269-3
pmc: PMC7785969
pii:
doi:

Types de publication

Journal Article Observational Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e21-e29

Subventions

Organisme : Wellcome Trust
ID : WT213038/Z/18/Z
Pays : United Kingdom
Organisme : NIDDK NIH HHS
ID : K23 DK125838
Pays : United States
Organisme : NIDDK NIH HHS
ID : K23 DK120899
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIDDK NIH HHS
ID : K01 DK120742
Pays : United States

Commentaires et corrections

Type : UpdateOf
Type : CommentIn

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Références

Nat Med. 2020 May;26(5):634-638
pubmed: 32273611
Wellcome Open Res. 2020 Aug 25;5:200
pubmed: 33997297
Lancet. 2020 May 2;395(10234):1420-1421
pubmed: 32325027
Lancet Respir Med. 2020 Nov;8(11):1061
pubmed: 32976756
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Science. 2020 Jun 19;368(6497):1362-1367
pubmed: 32371477
Nature. 2020 Aug;584(7820):257-261
pubmed: 32512579
Sci Data. 2021 Nov 22;8(1):297
pubmed: 34811392
Age Ageing. 2021 Jan 8;50(1):40-48
pubmed: 32986799
medRxiv. 2021 Feb 28;:
pubmed: 33655271
PLoS One. 2008 May 14;3(5):e2185
pubmed: 18478118
Nat Med. 2020 Jul;26(7):1037-1040
pubmed: 32393804
Nat Hum Behav. 2020 Sep;4(9):972-982
pubmed: 32848231
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404
Thorax. 2021 Jul;76(7):723-725
pubmed: 33376145
BMJ. 2020 Jul 3;370:m2679
pubmed: 32620558
Lancet Public Health. 2021 Jan;6(1):e30-e38
pubmed: 33308423
Int J Infect Dis. 2020 Apr;93:284-286
pubmed: 32145466
Nat Commun. 2020 Nov 12;11(1):5749
pubmed: 33184277

Auteurs

Thomas Varsavsky (T)

School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.

Mark S Graham (MS)

School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK. Electronic address: mark.graham@kcl.ac.uk.

Liane S Canas (LS)

School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.

Sajaysurya Ganesh (S)

Zoe Global, London, UK.

Joan Capdevila Pujol (J)

Zoe Global, London, UK.

Carole H Sudre (CH)

School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK; Medical Research Council Unit for Lifelong Health and Ageing, Department of Population Science and Experimental Medicine, and Centre for Medical Image Computing, Department of Computer Science, University College London, London, UK.

Benjamin Murray (B)

School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.

Marc Modat (M)

School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.

M Jorge Cardoso (M)

School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.

Christina M Astley (CM)

Division of Endocrinology and Computational Epidemiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

David A Drew (DA)

Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA.

Long H Nguyen (LH)

Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA.

Tove Fall (T)

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Maria F Gomez (MF)

Department of Clinical Sciences, Lund University Diabetes Centre, Malmö, Sweden.

Paul W Franks (PW)

Genetic and Molecular Epidemiology Unit, Lund University Diabetes Centre, Malmö, Sweden.

Andrew T Chan (AT)

Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA.

Richard Davies (R)

Zoe Global, London, UK.

Jonathan Wolf (J)

Zoe Global, London, UK.

Claire J Steves (CJ)

Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.

Tim D Spector (TD)

Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.

Sebastien Ourselin (S)

School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH